STOCKHOLM, SWEDEN - January 16, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces the filing of a patent application under the Patent Cooperation Treaty (PCT) process, a significant milestone in the intellectual property strategy for the company’s lead drug candidate, BupiZenge™. This filing follows the patent application submitted with …
